x
Filter:
Filters applied
- Focus on Sarcoidosis
- BMIRemove BMI filter
Publication Date
Please choose a date range between 2021 and 2021.
Keyword
- Sarcoidosis2
- ACE1
- Adiposity1
- Body Mass Index1
- Body mass index1
- Coronavirus1
- Coronavirus disease 20191
- Cough1
- COVID-191
- Diffusion Capacity of the Lungs for Carbon Monoxide1
- DLCO1
- EHRs1
- Electronic health record management systems1
- FeV11
- FVC1
- HCOs1
- Health Care Organizations1
- ICD-10-CM1
- International Classification of Diseases, Ninth Revision and tenth Revision, Clinical Modification1
- Interstitial lung disease1
- LCQ1
- Leicester Cough Questionnaire1
- Leicester cough questionnaire1
- QoL1
Focus on Sarcoidosis
2 Results
- Short communication
Abnormal FeV1 and body mass index are associated with impaired cough-related quality of life in sarcoidosis patients
Respiratory MedicineVol. 188106600Published online: September 7, 2021- Björn C. Frye
- Laura Potasso
- Erik Farin
- Urs Fichtner
- Surrinder Birring
- Joachim Müller-Quernheim
- and others
Cited in Scopus: 0Sarcoidosis is a granulomatous disease that mainly manifests within the lungs and may thereby impair lung function. Beyond and independently from organ impairment, sarcoidosis may affect quality of life which can be quantified by questionnaires. The Leicester Cough Questionnaire (LCQ) has been developed to assess cough-related quality of life. We analysed data from a prospectively collected cohort of sarcoidosis patients for validation of the German LCQ version. Our analyses demonstrated that LCQ values add additional information beyond routinely monitored parameters (e.g. - Original Research
Outcomes of SARS-CoV-2 infection in patients with pulmonary sarcoidosis: A multicenter retrospective research network study
Respiratory MedicineVol. 187106538Published online: July 22, 2021- Yousaf B. Hadi
- Dhairya A. Lakhani
- Syeda F.Z. Naqvi
- Shailendra Singh
- Justin T. Kupec
Cited in Scopus: 7Crude COVID-19 mortality and other clinical outcome measures are poor in pulmonary sarcoidosis cohort; however, propensity-matched analyses revealed no difference in outcomes, showing that higher mortality is driven by higher burden of comorbidities.